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Multiple sclerosis (MS) is an immune mediated inflammatory
diseases of the central nervous system characterized by focal
ovoid like lesions of demyelination seen on MRI(1,2). The
etiology of MS is unknown, however inflammation followed by
CNS demyelination and axonal degeneration are known to be
part of the pathologic processes that lead to the disease (1).
The mean age of onset of MS is 28-31 years old and tends to
affect women more often then men with a ratio of 2.3:1 (3,4) .
Other risk factors associated with MS include vitamin D
deficiency, smoking, and certain viruses (5). The pattern of the
disease can be classified as either Relapsing or Progressive
depending on whether the patient has periods with or without
symptoms (6). MS is diagnosed clinically with MRI used to
support the diagnosis. In cases where the diagnosis isn’t clear
the McDonald diagnostic criteria can be applied (2). The life
expectancy is reduced 7-14 years compared to the general
population with increased deaths from infection, cardiovascular
disease, respiratory disease, and suicide (7). Treatment can be
divided into acute flairs, chronic, and symptomatic. The acute
flairs are generally treated with steroids or plasma exchange,
while the chronic disease is generally treated with disease
modifying therapy (DMT)(5). No known treatment cures MS or
completely prevents progression, however, which has led to
many novel therapies. One of the promising therapies being
explored for the past 2 decades is autologous hematopoietic cell
transplants (AHCT).

Myeloma, lymphoma, and plasma cell disorders (8). AHCT
almost always leads to infertility. Studies show infertility in >98%
of patients receiving myeloablative stem cell transplant (9). One
study showed that out of 37,362 patients who received a stem
cell transplant, 232 of those patients (.6%) were successful in
becoming pregnant. 30 of those 232 patients used assistive
reproductive techniques (ART) to conceive (10). This high
infertility rate is likely secondary to treatment-related
gonadotoxicity (9). Even in Patients who have gonadal recovery,
the spontaneous pregnancy rate is <15% (11). Because of the
high rate of infertility secondary to gonadotoxicity, oocyte
retrieval and cryopreservation should be considered for any
patient undergoing AHCT treatment for MS and desires future
fertility.

AHCT is the process of collecting stem cells from either the
peripheral blood stream, destroying the cells in the body with
either radiation or chemotherapy, and then reestablish blood cell
production by reintroducing the collected stem cells. AHCT can
be divided into 3 categories: myeloablative, nonmyeloablative,
and reduced intensity conditioning (RIC). These categories are
differentiated whether the medicine employed is expected to
result in pancytopenia (myeloablative), lymphopenia but minimal
cytopenia (nonmyeloablative), or does not fit into either category
(RIC). AHCT has been used for the treatment of multiple

Case
The patient is a 24-year-old G0P0 who presented for fertility
preservation with a past medical history of depression, anxiety,
nephrolithiasis, and MS refractory to traditional medical therapy.
She was referred to a tertiary care center to undergo AHTC over
the summer for treatment of her MS. After thorough counseling
on options, medications, and risk, the patient decided to proceed
with oocyte cryopreservation.
The patient was started on combined estrogen/progesterone
birth control for 3 weeks in preparation for initiation of controlled
ovarian hyperstimulation, with baseline transvaginal ultrasound
(TVUS) demonstrating an endometrial stripe of 6mm and E2 of
22. Patient received daily Follistim 150IU/Menopur 75IU on cycle
day 1 to 6, followed by Follistim 150IU alone on cycle day 7 to 9.
Ganarelix 250mcg was given on cycle day 6 to 9. Serial TVUS
were performed on cycle days 5, 7, and 10 demonstrating
appropriate follicular development. E2 levels on cycle day 5, 7,
and 10 were 1100, 2497, and 4930, respectively. The decision
was made to proceed with trigger with Lupron on cycle day 10 for
oocyte retrieval on cycle day 12. Ultrasound guided needle
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aspiration was performed under conscious sedation on cycle day
12 with retrieval of 12 oocytes, or which 11 were mature and
underwent cryopreservation.

Discussion
This report demonstrates a case of successful oocyte retrieval in a
patient planning to receive AHCT treatment for MS who desires
future fertility. The need for fertility planning is well known for
patients undergoing stem cell transplant for other indications;
however, upon journal review the author notes this is a novel use
of ART for this clinical scenario. One can assume that the same
guidelines, complications, and fertility rates would be the same as
other indications, but as AHCT treatment for MS becomes more
prevalent further research should be carried out on the subject. As
with the other indications for stem cell transplant, any patient who
desires future fertility and is undergoing stem cell therapy for MS
should be referred to a reproductive endocrinologist prior to
receiving therapy.
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